




IMI2 : Innovative Medicines Initiative

Wébinaire d'information Call 22&23

14 Mai 2020



Statistiques IMI2



Données générales (au 7 mai 2020, Call 01 à 16, Dashboard de la CE)

- Nombre de projets déposés : 103
- Nombres de projets signés : 89
- Taux de succès : 86 %
- Nombre moyen de partenaires par consortium : 23
- Contribution moyenne de la CE par projet : 12 M€
- Coût total par projet : 25 M€
- Participations : 2064 Participations uniques : 831


- **Participation des PME**

245 participations

10,60% du budget reçu par les PME → Objectif de la CE de 20%

→ **Besoin d'augmenter la participation des PME au programme IMI**

Statistiques IMI2



Données générales (au 7 mai 2020, Call 01 à 16, Dashboard de la CE)

- Nombre de projets déposés : 103
- Nombres de projets signés : 89
- Taux de succès : 86 %
- Nombre moyen de partenaires par consortium : 23
- Contribution moyenne de la CE par projet : 12 M€
- Coût total par projet : 25 M€
- Participations : 2064 Participations uniques : 831

- **Participation des PME**

245 participations

10,60% du budget reçu par les PME → Objectif de la CE de 20%

→ **Besoin d'augmenter la participation des PME au programme IMI**

Statistiques IMI2

Données générales (au 7 mai 2020, Call 01 à Call 16, Dashboard de la CE)

Country	H2020 Participations	H2020 Net EU Contribution	H2020 SME Participations	H2020 SME Net EU Contribution	H2020 Participations to Coordination role	H2020 EU Contribution to Coordination role
United Kingdom	402	€ 252 947 825	35	€ 17 249 874	19	€ 111 634 613
Netherlands	201	€ 141 022 750	40	€ 14 789 872	19	€ 49 052 421
Germany	285	€ 115 348 306	40	€ 21 757 912	11	€ 21 668 246
France	232	€ 107 197 710	28	€ 14 118 409	6	€ 23 430 795
Spain	109	€ 102 925 262	20	€ 12 391 404	10	€ 36 115 863
Italy	109	€ 75 339 519	10	€ 3 802 750	5	€ 38 890 594
Belgium	176	€ 58 402 139	20	€ 5 949 143	4	€ 13 090 415
Switzerland	117	€ 44 387 844	5	€ 6 926 375	3	€ 9 350 646
Sweden	76	€ 30 249 662	7	€ 2 560 452	7	€ 10 180 962
Austria	37	€ 27 761 705	3	€ 2 146 150	2	€ 7 435 461
Ireland	18	€ 16 726 624	1	€ 137 500	1	€ 1 095 124
Sierra Leone	3	€ 22 318 597	0	€ 0	0	€ 0
Denmark	67	€ 16 925 782	6	€ 3 460 218	0	€ 0
Luxembourg	28	€ 11 304 580	10	€ 3 081 386	2	€ 890 856
Finland	28	€ 10 315 235	1	€ 149 250	0	€ 0

The Innovative Medicines Initiative


*Funding opportunities to support collaborations between
academia and industry*

Magali Poinot, Advisor to the Executive Director
IMI info day • France • 14.05.2020

IMI – Ecosystem for innovative collaborations

IMI is a **neutral platform** where **all involved** in drug development can engage in **open collaboration** on **shared challenges in areas of unmet medical needs**.

All partners needed to find transformative solutions to **reduce late stage attrition, speed patient access** and **improve health outcomes** and find solutions for a sustainable healthcare system



IMI – Europe's partnership for health

IMI2 Strategic Research Agenda

Health priorities aligned with WHO priorities

- Antimicrobial resistance
- Osteoarthritis
- Cardiovascular diseases
- Diabetes
- Neurodegenerative diseases
- Psychiatric diseases
- Respiratory diseases
- Immune-mediated diseases
- Ageing-associated diseases
- Cancer
- Rare/Orphan Diseases
- Vaccines

Axis of Research

- Target validation and biomarker research
- Adoption of innovative clinical trial paradigms
- Innovative medicines
- Patient-tailored adherence programmes

Over 11 500 researchers from an international, cross-sector community



IMI2 funding

(2014-2020)

IMI FUNDING MODEL

efpia



**public
contribution**
€1.638 bn

funding from
Horizon 2020

€ 3.276 bn
TOTAL IMI2 BUDGET

**IN-KIND PRIVATE
CONTRIBUTION**

€1.425 bn

EFPIA companies
receive no
funding

OTHER CONTRIBUTIONS
€213 MILLION

(Associated Partners, e.g.
charities, non-EFPIA companies)

EU funding goes to ▶

SMES

UNIVERSITIES

PATIENTS, REGULATORS...

◀ EFPIA contribute researchers, laboratories,
generation of data, curation of compounds,
and cash

Public and private partners collaborate in IMI2 projects

Accelerating research and
development

Speeding up patient access to
innovative treatments

Improving patient outcomes
and safety of medicines




What do we attack in IMI?

- IMI is not for everyone and it is not for everything
- But we can tackle some big things that other mechanisms cannot
- Some examples:
 - Pooling of assets from disparate sources (across the public/private divide) in order to do impactful things
 - Complex technology platforms that require scale for success
 - Catalysing new infrastructures representing significant gaps in the system
 - Tackling really big societal challenges that seem to be “stuck”
 - Problems where different stakeholder groups are required to be at the same table from day 1
 - Opportunities for technology convergence to be operationalised in high risk areas
 - New actors- new industrial sectors- important role for European SMEs
 - Areas that challenge the traditional thinking around the precompetitive space



EU landscape for health research – H2020



Participating in IMI projects

Attracting stakeholders

Any legal entity, regardless its place of establishment, carrying out work relevant to the Call objectives may be part of applicant consortia

But... not all participating entities are eligible for funding

Who is eligible for IMI funding?

- Academic institutions
- Small & medium-sized enterprises (SMEs)
- Mid-sized enterprises ($\leq$ €500m)
- Non-profit organisations e.g. research organisations, patient organisations, NGOs, public bodies, intergovernmental organisations etc.

Established in:

- **EU Member State**
- **Associated Country**

Other countries:

*No funding **unless participation deemed essential** by IMI2 JU for carrying out the action*

Art.1 Commission Delegated Regulation (EU) No 622/2014

Participation of SMEs, patient groups, regulators, non-pharma sectors

We encourage the participation of a wide range of health research and drug development stakeholders in our projects.

- SMEs and mid-sized companies
- Patient organisations
- Regulatory bodies
- Companies / organisations from related fields (e.g. diagnostics, animal health, IT, imaging etc...)

What's in it for SMEs?

- Forming new networks and **partnerships**
- Building **reputation** and **visibility**
- Perfecting **innovative services** and products - and being able to pitch them
- Access to **infrastructure, technology, knowledge and resources**
- **Learning industry standards.**
- Accelerating **business expansion**
- Access to **funding**: get 100% of their eligible costs reimbursed


What's in it for academia?

- Forming **new networks and partnerships with top teams**, often resulting in spin out projects and new funding opportunities.
- **Building reputation and visibility.** IMI research has a citation impact of nearly twice the EU average.
- **Access** to infrastructure, technology and resources, such as clinical trials, compounds, infrastructure and cutting-edge technology.
- **Learning industry standards** and gaining insight into the drug development process.
- Becoming more objectives-driven and impacts-oriented.
- **Access to funding:** in IMI projects, universities and research centres get 100% of their eligible costs reimbursed.

What's in it for patients?

- **Influence** research, and **identify gaps** from the perspective of patients and carers
- Receive **funding**
- Form **networks** with leading researchers
- **Access** to the latest science
- Take part in IMI work to help **improve health and wellbeing** in Europe
- Provide **patient perspective** to help shape IMI's portfolio and improve quality of IMI projects
- Contribute to **enhancing transparency** and trust between IMI and patients


How does an IMI project look like? HARMONY - Big Data / Oncology



53 organisations from 11 countries, working accross 7 hematological malignancies

Introduction to coming IMI2 Calls

Process from Call Launch to Project Launch



IMI2 Call 22 - Restricted call to maximise impact of IMI2 JU objectives and scientific priorities (*under approval*)

- Single-stage Call
- Restricted to the original consortia of actions funded under topics published in the IMI2 JU Annual Work Plans 2014-2015-2016, since only these actions are sufficiently advanced in their implementation to be considered for follow-up activities
- Limited to those topics where the corresponding Work Plan already pre-informed potential applicants about the possibility of a later restricted Call – see list on IMI website

IMI2 Call 23 – 6 topics under approval

Call launch expected on 23 June 2020

- Returning **clinical trial data** to study participants within a GDPR compliant and approved framework
- Modelling the impact of **monoclonal antibodies and vaccines** on the reduction of **antimicrobial resistance**
This topic is part of IMI's Antimicrobial Resistance (AMR) Accelerator programme.
- A **platform for accelerating biomarker discovery and validation** to support therapeutics development for **neurodegenerative diseases**
- Optimal treatment for patients with **solid tumours** in Europe through **artificial intelligence**
- Shortening the path to **rare disease diagnosis** by using new born **genetic screening and digital technologies**
- Behavioural model of factors affecting **patient adherence**

Expected consortia – Call 23


Stage 1 of two stage - Short Proposals

- **Consortia consisting of:**
 - IMI2 JU fundable legal entities carrying out activities relevant for achieving the project objectives
 - additional legal entities carrying out activities relevant for achieving the project objectives.

IMI2 Calls 22 / 23 – Key dates

- Call launch: expected on 23 June 2020
- **Draft** topics text **already published** on the [IMI website](#)
- **Webinar** topic presentations: mid-end June 2020
as well as SME dedicated webinar
Rules & Procedures webinar
- Submission through the EU Funding & Tenders Portal
[SEDIA](#)

A single set of evaluation criteria



- As of Call 18, the evaluation criteria, thresholds and proposal templates have been revised
- Two-stage evaluation: all three criteria considered at both stages
- Thresholds and weighting in the **Call documents** depending two-stages/single stage
- Minimum of **3 independent experts**

Each proposal **evaluated 'as it is'**, not as 'what could be'

Call 23 – two stages

- At stage 1 evaluation the **budget** is evaluated under criterion 3 'Quality and Efficiency of the Implementation'
- Applicants will need to provide a breakdown of costs (and not only the overall amount, as previously the case), by filling in the budget table in Part A of the proposal

Budget for the proposal

Participant	Country	(A) Direct personnel costs/€	(B) Other direct costs/€	(C) Direct costs of sub- contracting/€	(D) Direct costs of providing financial support to third parties/€	(E) Costs of in-kind contributions not used on the beneficiary's premises/€	(F) Indirect Costs / € (=0.25(A+B-E))	(G) Special unit costs covering direct & indirect costs / €	(H) Total estimated eligible costs / € (=A+B+C+D+F +G)	(I) Reimburse- ment rate (%)	(J) Max.EU Contribution / € (=H*I)	(K) Requested EU Contribution/ €
		?	?	?	?	?	?	?	?	?	?	?
		0	0	0	0	0	0,00	0	0,00	100	0,00	0,00
Total		0	0	0	0	0	0,00	0	0,00		0,00	0,00

Intellectual Property framework

IMI IP policy to support innovation

- Opportunity of further development and/or validation of background assets
- Background and sideground assets protected (no transfer)
- New results owned by the generator(s) and right to transfer ownership / for non-exclusive license
- Result owner to design on the best protection modalities
- Access to expertise from the other partners on equal basis
- Access rights for exploitation purposes to be negotiated on a case-by-case basis
- Dissemination subject to conditions, such as respect of the legitimate interests

THANK YOU

Visit our new website

www.imi.europa.eu

Sign up our newsletter

bit.ly/IMInewsletter

Follow us on Twitter


[@IMI_JU](https://twitter.com/IMI_JU)

Join our LinkedIn group

bit.ly/LinkedInIMI

Email us


infodesk@imi.europa.eu





Conseils pour le montage


Anticiper sa participation au programme IMI



Appels IMI publiés au fil de l'eau:


- Ne pas attendre la publication officielle des appels
- Pré-publication des futurs appels IMI 2 mois avant l'ouverture officielle
 - site IMI [Future Topics page](#)
 - Suivre l'actualité de IMI sur [Twitter](#)
 - Rejoindre le groupe [LinkedIn group](#)
 - S'abonner à la [newsletter mensuelle IMI](#)

S'informer



- Participer aux info-days
- Participer aux évènements IMI <https://www.imi.europa.eu/news-events/events>
- Participer aux Webinaires IMI mis en place dès la publication des appels

Trouver des partenaires et/ou un consortium en cours de montage (1)




- Contacter votre réseau
- Utiliser les réseaux sociaux: LinkedIn group
- Identifier les spécialistes du domaine et contact via conférences scientifiques
- Contacter le réseau EEN pour trouver des PME
<http://www.een-france.fr/reseau/115386-enterprise-europe-network-france>




L'Europe à la portée de votre entreprise

Trouver des partenaires et/ou un consortium en cours de montage (2)



- Participer aux webinaires organisés par IMI: liste des participants
- Projets cités dans les appels à projets IMI:
« potential synergies with existing consortia »
 - Liste de projets IMI sur le site : contact du coordinateur
 - Site web des projets: autres contacts

Trouver des partenaires et/ou un consortium en cours de montage (3)



- Utiliser les plateformes de recherche de partenaires :
déposer une demande /consulter les propositions

→ Portail du participant:

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/partner-search>

Publication d'une fiche: LEAR (legal entity appointed representative)

→ Plateforme de recherche de partenaires IMI mise en place par le PCN

<http://www.imi-partnering.de/>

Publication d'une fiche: création d'un compte



Welcome to the IMI2 Partnering Platform


The IMI2 Partnering Platform facilitates networking among universities, research and patient organizations, SMEs and industry interested in participating in the **Innovative Medicines Initiative Joint Undertaking (IMI JU)**. The Innovative Medicines Initiative is a unique Public-Private Partnership (PPP) between the pharmaceutical industry represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Communities represented by the European Commission. The IMI2 Partnering Platform offers you to search for partners and to present your expertise to the IMI2 research community.

By **completing and activating your profile** you **publish your partnering profile** to all users and present your collaboration offers.

The **partner search function** is available for all users, also for those who do not publish their partnering profile. It assists you in finding suitable cooperation partners for future IMI Calls.

More information on the **Innovative Medicines Initiative Joint Undertaking** can be found on the **official IMI JU website**:
<http://www.imi.europa.eu/>



Ou trouver de l'aide?



- Contacter votre cellule Europe (identification des partenaires, aide au montage de projet...)
- Contacter IMI pour des informations sur les appels infodesk@imi.europa.eu
- Contacter le PCN santé pcn-sante@recherche.gouv.fr

Où trouver de l'aide?

PCN Santé, évolution démographique et bien-être



pcn-sante@recherche.gouv.fr
<http://www.horizon2020.gouv.fr>

aviesan
alliance nationale
pour les sciences de la vie et de la santé



Virginie Sivan
Représentante au Comité
de Programme